Definition of a small core transcriptional circuit regulated by AML1-ETO

被引:40
|
作者
Stengel, Kristy R. [1 ]
Ellis, Jacob D. [1 ]
Spielman, Clare L. [1 ]
Bomber, Monica L. [1 ]
Hiebert, Scott W. [1 ,2 ]
机构
[1] Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA
基金
美国国家卫生研究院;
关键词
ACUTE MYELOID-LEUKEMIA; GENOME-WIDE; T(8/21) AML; 21; TRANSLOCATION; FUSION PARTNER; GENE; IDENTIFICATION; DIFFERENTIATION; T(8-21); BINDING;
D O I
10.1016/j.molcel.2020.12.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Transcription factors regulate gene networks controlling normal hematopoiesis and are frequently deregulated in acute myeloid leukemia (AML). Critical to our understanding of the mechanism of cellular transformation by oncogenic transcription factors is the ability to define their direct gene targets. However, gene network cascades can change within minutes to hours, making it difficult to distinguish direct from secondary or compensatory transcriptional changes by traditional methodologies. To overcome this limitation, we devised cell models in which the AML1-ETO protein could be quickly degraded upon addition of a small molecule. The rapid kinetics of AML1-ETO removal, when combined with analysis of transcriptional output by nascent transcript analysis and genome-wide AML1-ETO binding by CUT&RUN, enabled the identification of direct gene targets that constitute a core AML1-ETO regulatory network. Moreover, derepression of this gene network was associated with RUNX1 DNA binding and triggered a transcription cascade ultimately resulting in myeloid differentiation.
引用
收藏
页码:530 / 545.e5
页数:22
相关论文
共 50 条
  • [1] PLaCatinG AML1-ETO Comment
    Azam, Mohammad
    BLOOD, 2022, 139 (07) : 959 - 961
  • [2] JAKing up AML1-ETO
    Crispino, John D.
    BLOOD, 2012, 120 (04) : 703 - 704
  • [3] Fusion protein AML1-ETO downregulates the transcriptional activity of PU.1.
    Vangala, RK
    Heiss, MS
    Singh, SM
    Rangatia, J
    Reddy, VA
    Elsaesser, A
    Cicenas, J
    Pelicci, P
    Tenen, DG
    Hiddemann, W
    Behre, G
    BLOOD, 2000, 96 (11) : 500A - 500A
  • [4] Development of small molecule inhibitor of the AML1-ETO oncoprotein.
    Grembecka, J
    Graf, K
    Newman, M
    Zhou, YP
    Cheney, M
    Speck, NA
    Brown, ML
    Bushweller, JH
    BLOOD, 2005, 106 (11) : 436A - 436A
  • [5] The transcriptional and epigenetic targets of the AML associated oncofusion proteins AML1-ETO and PML-RARα
    Martens, J.
    Laakso, M.
    Brinkman, A.
    Francoijs, K-J.
    Simmer, F.
    Altucci, L.
    Vellenga, E.
    Stunnenberg, H.
    FEBS JOURNAL, 2010, 277 : 31 - 31
  • [6] The Acetylation of AML1-ETO Is Required for Leukemogenesis
    Wang, Lan
    Gural, Alexander
    Perna, Fabiana
    Sun, Xiaojian
    Zhao, Xinyang
    Xu, Haiming
    Hatlen, Megan A.
    Huang, Gang
    Liu, Fan
    Xu, Hao
    Deblasio, Tony
    Mehendez, Silvia
    Voza, Francesca
    Roeder, Robert
    Nimer, Stephen
    BLOOD, 2010, 116 (21) : 671 - 671
  • [7] Structure of the AML1-ETO NHR3-KA(RIIα) Complex and Its Contribution to AML1-ETO Activity
    Corpora, Takeshi
    Roudaia, Liya
    Oo, Zaw Min
    Chen, Wei
    Manuylova, Ekaterina
    Cai, Xiongwei
    Chen, Michael J.
    Cierpicki, Tomasz
    Speck, Nancy A.
    Bushweller, John H.
    JOURNAL OF MOLECULAR BIOLOGY, 2010, 402 (03) : 560 - 577
  • [8] Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity
    Park, Sangho
    Chen, Wei
    Cierpicki, Tomasz
    Tonelli, Marco
    Cai, Xiongwei
    Speck, Nancy A.
    Bushweller, John H.
    BLOOD, 2009, 113 (15) : 3558 - 3567
  • [9] ELA2 is regulated by hematopoietic transcription factors, but not repressed by AML1-ETO
    J Lausen
    S Liu
    M Fliegauf
    M Lübbert
    M H Werner
    Oncogene, 2006, 25 : 1349 - 1357
  • [10] ELA2 is regulated by hematopoietic transcription factors, but not repressed by AML1-ETO
    Lausen, J
    Liu, S
    Fliegauf, M
    Lübbert, M
    Werner, MH
    ONCOGENE, 2006, 25 (09) : 1349 - 1357